HIV patients respond well to Gilead's 4-drug combo in study

09/19/2011 | Bloomberg

Quad, an investigational four-drug cocktail by Gilead Sciences, achieved a 90% response rate among HIV patients in a Phase III trial, compared with 87% for those given Atripla, an approved treatment combining Gilead's two-in-one pill Truvada and Bristol-Myers Squibb's Sustiva. Gilead aims to file by year-end for FDA approval of Quad, said chief scientific officer Norbert Bischofberger.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN